NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $70,200 | -84.0% | 22,000 | -81.0% | 0.01% | -90.4% |
| Q2 2022 | $439,000 | -88.5% | 115,600 | -83.8% | 0.05% | -51.9% |
| Q1 2022 | $3,834,000 | +989.2% | 711,400 | +2636.2% | 0.11% | +1442.9% |
| Q4 2021 | $352,000 | +3.2% | 26,000 | +36.8% | 0.01% | -30.0% |
| Q3 2021 | $341,000 | -84.5% | 19,000 | -82.7% | 0.01% | -81.5% |
| Q1 2021 | $2,200,000 | +56.7% | 110,000 | +33.3% | 0.05% | +100.0% |
| Q4 2020 | $1,404,000 | +20.8% | 82,500 | +17.9% | 0.03% | -35.7% |
| Q3 2020 | $1,162,000 | – | 70,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |